Seftel, M. D., Kuruvilla, J., Kouroukis, T., Banerji, V., Fraser, G., Crump, M., Kumar, R., Chalchal, H. I., Salim, M., Laister, R. C., Crocker, S., Gibson, S. B., Toguchi, M., Lyons, J. F., Xu, H., Powers, J., Sederias, J., Seymour, L., & Hay, A. E. (2017). the CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group. Leukemia & lymphoma, 58(6), 1358–1365. http://access.bl.uk/ark:/81055/vdc_100042870833.0x00000f